We measured suPAR levels in a recent prospective multicenter crossover trial comparing the efficacy of MMF and CsA in pediatric patients with minimal change disease ( MCD ) and frequently relapsing steroid-sensitive nephrotic syndrome ( FR-SSNS ) .